Novartis announce plans to return rights of Oncology antibody to Aveo

05 July 2018
Pharma

In a deal valued at at least $326 million just announced, Novartis will return the Oncology antibody to Aveo. The AV-380 antibody targets GDF15. In an SEC filing, Aveo said it has received a 'notice of termination' of the license agreement with Novartis. This agreement gave Novartis exclusive worldwide right to develop and commercialise AV-380 and related Aveo antibodies that inhibit GDF15.

Though Novartis regard the programme 'an important asset', they also maintain that development delays, and ultimately an internal decision not to continue further development as the key reason to hand back the license. Novartis also said that changes in management and strategic priorities within the firm were central to their decision.

This news is not totally unexpected, as Aveo were involved with filing a dispute notification regarding Novartis’ compliance with its 'diligence obligations' as part of the development of AV-380. Aveo had stated that 'if the parties are unable to resolve the dispute at the management level, an arbitration could be commenced'.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to elena.di@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharmaceutical Product Information Management System Market Report 2020-2030

Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.

19 October 2020

Read

Visiongain Publishes Pulmonary/Respiratory Drug Delivery Market Report 2020-2030

The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.

12 October 2020

Read

Visiongain Publishes Real-World Evidence (RWE) Solutions Market Report 2020-2030

We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

02 October 2020

Read

Visiongain Publishes mRNA Vaccines Market Report 2021-2031

The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.

02 October 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever